Ｏｂｊｅｃｔｉｖｅ　Using Meta-analysis to systematically evaluate the impact of parecoxibon on postoperative cognitive dysfunction (POCD) of senior patients after non-cardiac surgery.　Methods　Literature on the impact of parecoxibon on POCD of senior patients after non-cardiac surgery using randomized controlled trial (RCT) are searched from the following databases: PubMed, EMBASE, The Cochrane Library, CNKI, VIP, WanFangData, Chinese Biomedical Literature Database. All literature from the database until 2016 July 30th are included in the search. The studies were further selected based on incorporation and exclusion criteria. The data quality was evaluated based on improved Jadad scales. The meta-analysis was performed using RevMan5.2 software.　Results　18 RCT studies from 17 publications, coming from 1 082 patients, were included in the analysis. The results of meta-analysis shows that: compared to control group, parecoxib can reduce the rate of POCD 3 day post-surgery (RR=0.50，95%CI=0.37-0.68), but not 7 day post-surgery ［relative risk(RR)=0.71，95%CI=0.49-1.04］. Parecoxib can increase the MMSE score of patients 1 day post-surgery ［mean difference(MD)=1.2，95%CI=0.39-2.02］ and 3 day post-surgery (MD=0.97，95%CI=0.44-1.51), but has no significant effect on 7 day post-surgery MMSE score (MD=0.17，95%CI=-1.02-1.36).　Conclusions　The literature suggests that parecoxib can increase MMSE score and improve post-surgery cognitive function temporally, but has no significant effect on post-surgery cognitive function after 7 day post-surgery.